FDA To Consider Behind-The-Counter Drugs

Law360, New York (October 4, 2007, 12:00 AM EDT) -- The U.S. Food and Drug Administration announced on Thursday that it will consider offering a third class of drugs, sold from behind pharmacy counters, in addition to traditional prescription and over-the-counter drugs.

In a notice printed in Thursday’s issue of the U.S. Federal Register, the FDA announced that it would hold a public meeting on Nov. 14 on so-called behind-the-counter drugs.

“The FDA is interested in obtaining public comment as it explores the public health benefit of certain drugs being available without a prescription but only...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.